vs

Side-by-side financial comparison of Phreesia, Inc. (PHR) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

Phreesia, Inc. is the larger business by last-quarter revenue ($120.3M vs $83.1M, roughly 1.4× PROCEPT BioRobotics Corp). Phreesia, Inc. runs the higher net margin — 3.5% vs -38.1%, a 41.6% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 12.7%).

Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

PHR vs PRCT — Head-to-Head

Bigger by revenue
PHR
PHR
1.4× larger
PHR
$120.3M
$83.1M
PRCT
Growing faster (revenue YoY)
PRCT
PRCT
+7.5% gap
PRCT
20.2%
12.7%
PHR
Higher net margin
PHR
PHR
41.6% more per $
PHR
3.5%
-38.1%
PRCT

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
PHR
PHR
PRCT
PRCT
Revenue
$120.3M
$83.1M
Net Profit
$4.3M
$-31.6M
Gross Margin
64.9%
Operating Margin
3.1%
-4.1%
Net Margin
3.5%
-38.1%
Revenue YoY
12.7%
20.2%
Net Profit YoY
129.7%
-27.9%
EPS (diluted)
$0.07
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHR
PHR
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$120.3M
$76.4M
Q3 25
$117.3M
$83.3M
Q2 25
$115.9M
$79.2M
Q1 25
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
Q2 24
$53.4M
Net Profit
PHR
PHR
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$4.3M
$-29.8M
Q3 25
$654.0K
$-21.4M
Q2 25
$-3.9M
$-19.6M
Q1 25
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
Q2 24
$-25.6M
Gross Margin
PHR
PHR
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
PHR
PHR
PRCT
PRCT
Q1 26
-4.1%
Q4 25
3.1%
-40.6%
Q3 25
-1.3%
-27.8%
Q2 25
-2.8%
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
-50.3%
Net Margin
PHR
PHR
PRCT
PRCT
Q1 26
-38.1%
Q4 25
3.5%
-39.1%
Q3 25
0.6%
-25.7%
Q2 25
-3.4%
-24.7%
Q1 25
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
Q2 24
-48.0%
EPS (diluted)
PHR
PHR
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.07
$-0.54
Q3 25
$0.01
$-0.38
Q2 25
$-0.07
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHR
PHR
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$106.4M
$245.6M
Total DebtLower is stronger
$3.4M
$51.7M
Stockholders' EquityBook value
$320.3M
$347.7M
Total Assets
$423.5M
$487.1M
Debt / EquityLower = less leverage
0.01×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHR
PHR
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$106.4M
$286.5M
Q3 25
$98.3M
$294.3M
Q2 25
$90.9M
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
PHR
PHR
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$3.4M
$51.6M
Q3 25
$4.6M
$51.6M
Q2 25
$6.2M
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PHR
PHR
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$320.3M
$365.9M
Q3 25
$298.0M
$380.3M
Q2 25
$282.2M
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
PHR
PHR
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$423.5M
$508.1M
Q3 25
$408.6M
$511.5M
Q2 25
$400.4M
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
Q2 24
$374.4M
Debt / Equity
PHR
PHR
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.01×
0.14×
Q3 25
0.02×
0.14×
Q2 25
0.02×
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHR
PHR
PRCT
PRCT
Operating Cash FlowLast quarter
$15.5M
Free Cash FlowOCF − Capex
$12.2M
FCF MarginFCF / Revenue
10.1%
Capex IntensityCapex / Revenue
2.7%
Cash ConversionOCF / Net Profit
3.62×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHR
PHR
PRCT
PRCT
Q1 26
Q4 25
$15.5M
$-10.3M
Q3 25
$14.8M
$-6.6M
Q2 25
$14.8M
$-15.0M
Q1 25
$-17.0M
Q4 24
$-32.4M
Q3 24
$-18.8M
Q2 24
$-15.7M
Free Cash Flow
PHR
PHR
PRCT
PRCT
Q1 26
Q4 25
$12.2M
$-12.2M
Q3 25
$13.1M
$-9.5M
Q2 25
$11.3M
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
PHR
PHR
PRCT
PRCT
Q1 26
Q4 25
10.1%
-15.9%
Q3 25
11.1%
-11.4%
Q2 25
9.8%
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
PHR
PHR
PRCT
PRCT
Q1 26
Q4 25
2.7%
2.4%
Q3 25
1.5%
3.4%
Q2 25
3.0%
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%
Cash Conversion
PHR
PHR
PRCT
PRCT
Q1 26
Q4 25
3.62×
Q3 25
22.68×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PHR
PHR

Subscription And Services$55.5M46%
Network Solutions$37.4M31%
Payment Processing Fees$27.4M23%

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons